“视网膜脉络膜疾病诊治研究”北京市重点实验室于2013年认定，是集医疗、教学、科研为一体的现代化研究基地。实验室依据学科的自身特点和优势，瞄准视网膜脉络膜疾病领域的前沿，通过对疾病发病机制的深入研究，寻求干预策略，开展转化研究，降低视网膜脉络膜疾病致残致盲率。实验室现有科研设备完善，包括基因测序仪、流式细胞仪、动物实验专用手术显微镜、实时定量PCR仪、荧光显微镜等，满足开展临床基础研究的需要，为承担重大科研项目提供有力的条件支撑。

　　实验室瞄准视网膜脉络膜疾病发病机制的前沿问题，研究重点关注：1. 黄斑病的发病机制和临床诊治，2. 寻找视网膜脉络膜血管性、增殖性疾病的分子机制及潜在干预靶点，3. 建立中心性浆液性渗出性视网膜病变的干预新策略，4.视网膜脉络膜变性及营养不良病变的诊治；5.感染性与非感染性葡萄膜炎、眼内淋巴瘤等免疫相关性眼病的早期诊断，6.葡萄膜及视网膜肿瘤的治疗，7. 遗传眼病的基因研究。

　　“视网膜脉络膜疾病诊治研究”北京市重点实验室共有专职人员39人，其中包括博士生导师5人，国际眼科学院院士1人、中华医学会眼科学分会前任主任委员1人、中华眼底病学组前任组长1人、中华眼底病学组副组长1人、11名学组委员。中华眼底病杂志总编1人、9名专家承担中华系列杂志编委。在青年培养方面，有教育部新世纪优秀人才1人，北京市科技新星3人，北京大学人民医院学术新星4人。同时，与荷兰莱顿大学Martin Jarger教授共同开展共建实验室，聘请Martin Jarger为特聘教授。实验室聘请美国佛罗里达大学庞继景教授（Pang Ji-jing）为客座教授。

　　自1990年起作为教育部博士学位授予点，1991年起就一直作为国家级眼科学继续教育基地，于2000年被评为“211”和“985”重点学科、2002年被评为国家教育部重点学科、2006年成为国家药品监督管理局眼科药物研究基地，2007年成为卫生部和北京市眼科专科医师培训基地、2008年成为北京市专科医师考试基地，2009年成立人民眼科中心暨眼科研究所，2012年被评为 “视觉损伤与修复(北京大学)”教育部重点实验室、2013年被评为“视网膜脉络膜疾病诊治研究”北京市重点实验室。2016年成立北京大学医学部眼视光学院，由赵明威教授担任院长，并在人民医院成立眼视光中心，眼科研究所更名为眼病与视光医学研究所。

　　研究成果获得“教育部全国高等学校科技进步奖一等奖”2项、“教育部全国高等学校科技进步奖二等奖”2项、“北京市科学技术二等奖”1项。

　　实验室围绕视网膜脉络膜疾病的发病机制进行深入研究，获得了一系列研究成果：1. 针对年龄相关性黄斑变性，首次发现了东亚人群AMD易感基因UBE3D；2. 围绕视网膜血管性疾病，从分子机制，和临床新型治疗进行研究，发现治疗视网膜新生血管潜在靶点；3. 建立中心性浆液性渗出性视网膜病变的干预新策略；4. 创新性定义了黄斑裂孔愈合指数（MHCI）；5. 建立眼病原学检测，遗传性眼病基因检测平台。

　　先后申请了国家级、部委级科研课题60余项，包括973项目（子课题）、863项目、985项目、“十一五”“十二五”国家科技计划支撑项目、国家自然科学基金，国际合作项目及各类省部级项目。在国际、国家级核心刊物上发表中文文章300余篇，SCI文章200余篇，国家发明专利12项。

　　

　　机构负责人：赵明威

　　联系人：黄旅珍

　　邮箱：huanglvzhen@126.com

　　电话：13810683863

　　地址：北京市西城区阜成门内大街133号

　　网址链接：http://sys.rmyk.cn/

　　

　　

　　Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases

　　Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases was founded in 2013. It is a research base of medical treatment, education and scientific research. The laboratory aims at providing a theoretical basis for the prevention and treatment of visual impairment, exploring the mechanism of vision loss and restoration, finding new ways for clinical therapies, and carrying on clinical translational research in order to effectively reduce the incidence of visual impairment in our nation. The equipments of our institute include DNA sequencing system, research flow cytometer, surgical microscope, PCR Amplifier, and fluorscence microscopic imaging system. These equipments  supported the original vital research platforms and invested to provide strong support for developing proteomics and genomics research.

　　Our research field focus on retinal and choroid diseases, involving：1. Nosogenesis and clinical treatment of macular diseases, 2. Molecular mechanism of retinal neovascularization diseases, and looking for potential therapeutic target for the clinical management of retinal neovascularization diseases, 3. Try to find out effective therapeutic method of central serous chorioretinopathy (CSC), 4. Dignosis and treatment of degeneration diseases of chorioretinopathy and dystrophy diseases of chorioretinopathy, 5. Early diagnosis of eyeimmunological diseases,such as uveitis and Intraocular lymphoma, 6. Treatment of retinal and choroidal tumor, 7. Gene therapy research of inherited eye diseases.

　　There are currently more than 30 staff in the Eye center, including  5 doctoral supervisors , 1 academician of the international ophthalmology College, 1 former president of the Chinese Ophthalmology Society, 1 chief editor of the Chinese Ocular Fundus Diseases Journal, 1 former president and 1 vice-president of the Chinese Ocular Fundus Diseases Society, and 11 committee members of the Chinese Ophthalmology Society. 1 chief editor of the Chinese Journal of Ocular Fundus Diseases , and 9 experts served as the editorial board member of the Chinese Journal of Medicine. 1 New Century Excellent Talents, 3Beijing Nova, 4 Peking University People's Hospital academic star. We also invited Martin Jargeras Distinguished Professor, Pang Ji-jingas Visiting Professor.

　　Ophthalmology Department of PKUPH was authorized as a key discipline of Project 211 and Project 985 in 2000. The Eye Center is doctorate-accredited by the Ministry of Education, a postdoctoral scientific research station, a training center for ophthalmologic specialists of the Ministry of  Health and the Beijing Municipal Health Bureau, a test center for ophthalmologic specialists of the Beijing Municipal Health Bureau, a drug research center of the SFDA, and a national continuing education center. Eye Center and Eye Institute of PKUPH were set up in 2009. The lab was authorized as Key Laboratory of Vision Loss and Restoration of  Education Ministry in 2012, Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid in 2013. Optometry College of Peking University Health Science Center, Optometry Center of PKUPH, and Eye Diseases and Optometry Medical Research Institute of PKUPH were established in 2016.

　　Four provincial and public organizational prizes have been awarded, 3 first or second prizes of advances in science and technology of institution of higher education of the Ministry of Education have been authorized.

　　Our researches have received significant achievements: 1. Our findings first indicate that the UBE3D may play an important role in pathogenesis of neovascular AMD in East Asian Populations, 2. focus on molecular mechanism of retinal neovascularization diseases, and found potential therapeutic target for the clinical management of retinal neovascularization diseases, 3.found effective therapeutic method of central serous chorioretinopathy (CSC), 4. Formulated the new MHCI(a new macular hole closure index )which could be an easily measured and accurate predictive index for postoperative anatomical outcomes, 5. esteblished clinical laboratory tests, including Cytokine detection of vitreous and aqueous humor，genetic test of eye inherited diseases.

　　Till now, more than 60 research projects have been undertaken in our research institute, including  “973”grants, “863”grants, “985”projects,  national “eleventh-five-year”and “twelfth-five-year”supportive funding, National Science Foundation (NSF) grants, international collaboration study, and other provincial grants. Based on these researches, more than 300 articles have been published in Chinese, 200 have been published as SCI papers, and 12 patents have been authorized by the National Patent Office.

　　

　　Director: Zhao Mingwei

　　Contact: Huang Lvzhen

　　Email: huanglvzhen@126.com

　　TEL: 13810683863

　　Address: No. 133 Fuchengmen Inner Street , Xicheng District, Beijing, China

　　Website: http://sys.rmyk.cn/